Recognition and treatment of idiopathic pulmonary fibrosis.

Détails

ID Serval
serval:BIB_F8421E86C0B9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Recognition and treatment of idiopathic pulmonary fibrosis.
Périodique
Drugs
Auteur(s)
Nicod L.P.
ISSN
0012-6667[print], 0012-6667[linking]
Statut éditorial
Publié
Date de publication
1998
Volume
55
Numéro
4
Pages
555-562
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
The diagnosis of idiopathic pulmonary fibrosis can be made only after exclusion of other entities such as neoplasm, toxic treatments, collagen vascular diseases, occupational exposure or granulomatous diseases, such as sarcoidosis. The repercussions on gas exchanges are the most reliable indications of the severity of the disease, the measure of lung volume or chest x-rays alone often being misleading. Biopsies obtained during transbronchial procedures by thoracoscopies or thoracotomy are of great help, but mainly to rule out other diseases. In many cases, only a high resolution computerised tomography (CT) scan and bronchoalveolar lavage are performed to rule out infection or tumour and to assess the inflammatory state of the disease. Due to the fact that barely a quarter of patients respond to corticosteroids alone, cytostatics (in particular azathioprine) are often prescribed simultaneously with low dose corticosteroids, either initially or after an unsuccessful trial of corticosteroids. Cyclosporin has been useful for only a limited number of patients. Colchicine has been shown useful in an open trial but its role still needs to be assessed. Anticytokine therapy and the role of substances such as relaxin are still at the experimental stage. Lung transplantation is now a therapeutic option for selected patients.
Mots-clé
Adrenal Cortex Hormones/therapeutic use, Colchicine/therapeutic use, Cyclosporine/therapeutic use, Cytokines/antagonists & inhibitors, Gout Suppressants/therapeutic use, Humans, Immunosuppressive Agents/therapeutic use, Lung Transplantation, Pulmonary Alveoli/pathology, Pulmonary Alveoli/ultrastructure, Pulmonary Fibrosis/pathology, Pulmonary Fibrosis/therapy, Randomized Controlled Trials as Topic
Pubmed
Web of science
Création de la notice
19/02/2010 19:45
Dernière modification de la notice
03/03/2018 22:51
Données d'usage